Bionical adds Emas Pharma in strategic acquisition
pharmafile | November 11, 2016 | News story | Medical Communications, Sales and Marketing | Bionical, Emas pharma, acquistion
Bionical, an integrated outsourced specialist to the pharmaceutical, biotechnology and public health industry, has announced the acquisition of Emas Pharma. Emas provides pharmaceutical and device development services worldwide and partners with specialist pharma and biotech companies.
The acquisition will see Bionical’s worldwide clinical services business expand its reach in the global healthcare industry. Emas brings with it a global network with offices in the UK, the US, Canada, Australia and Ireland. The move will see Emas continue to operate as a separate business but with CEO, Peter Kennerley, joining the board of Bionical. Emas is the Bionical’s third acquisition in just over a year.
Graham McIntosh, CEO of Bionical, commented: “Emas Pharma is a fantastic business with great people and an excellent reputation. Emas’s services are highly complementary to Bionical’s existing clinical trial services and the acquisition creates opportunities for both businesses to bring enhanced services to their clients. We are very pleased Peter Kennerley, Liz McCann and the Emas team are now a part of Bionical and I look forward to working with them to continue the global growth of Emas.”
Dr Peter Kennerley, CEO of Emas Pharma, commented: “We are delighted to join the Bionical group, which is a perfect synergy for Emas Pharma. Being part of a wider family of companies means that we will be offering our clients an even broader range of services to complement our current offerings; from nurse specialists to help track patients lost to follow up, to call centres for Medical Information and from Clinical Trial Supply support to healthcare communications. Liz and I are proud of the excellent reputation for high quality, cost effective support that Emas has built up over the years. We know that joining Mac and the Bionical team will help us extend that reputation even further.”
Ben Hargreaves
Related Content
Abbott to boost heart valve therapy portfolio with acquisition of Cephea Valve Technologies
As mergers and acquisitions pick up again for the New Year, Abbott has revealed plans …
Lonza in $5.5 billion deal to acquire Capsugel
Lonza, the Basel-based supplier to the pharmaceutical, biotech and nutrition industry, has announced that it …
North 51 acquired by Bionical
North 51 Ltd, a Nottingham-based healthcare company has been acquired by Bionical in a multi-million …
